Replies to post #128569 on Biotech Values

[genisi]

Looks like you were right about Lucentis PRN

Bimonthly dosing (after the initial loading period) is already the de facto SoC for Lucentis in AMD, and the CATT study produced no data to change this. So, like it or not, bimonthly dosing of Lucentis is what Trap will have to compete against in the real world.

(#msg-62560113)